TY - JOUR T1 - Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial JF - medRxiv DO - 10.1101/2021.01.08.20248149 SP - 2021.01.08.20248149 AU - Florence Ader AU - Nathan Peiffer-Smadja AU - Julien Poissy AU - Maude Bouscambert-Duchamp AU - Drifa Belhadi AU - Alpha Diallo AU - Christelle Delmas AU - Juliette Saillard AU - Aline Dechanet AU - Noémie Mercier AU - Axelle Dupont AU - Toni Alfaiate AU - François-Xavier Lescure AU - François Raffi AU - François Goehringer AU - Antoine Kimmoun AU - Stéphane Jaureguiberry AU - Jean Reignier AU - Saad Nseir AU - François Danion AU - Raphael Clere-Jehl AU - Kévin Bouiller AU - Jean-Christophe Navellou AU - Violaine Tolsma AU - André Cabie AU - Clément Dubost AU - Johan Courjon AU - Sylvie Leroy AU - Joy Mootien AU - Rostane Gaci AU - Bruno Mourvillier AU - Emmanuel Faure AU - Valérie Pourcher AU - Sébastien Gallien AU - Odile Launay AU - Karine Lacombe AU - Jean-Philippe Lanoix AU - Alain Makinson AU - Guillaume Martin-Blondel AU - Lila Bouadma AU - Elisabeth Botelho-Nevers AU - Amandine Gagneux-Brunon AU - Olivier Epaulard AU - Lionel Piroth AU - Florent Wallet AU - Jean-Christophe Richard AU - Jean Reuter AU - Thérèse Staub AU - Maya Hites AU - Marion Noret AU - Claire Andrejak AU - Gilles Peytavin AU - Bruno Lina AU - Dominique Costagliola AU - Yazdan Yazdanpanah AU - Charles Burdet AU - France Mentre AU - on behalf of the DisCoVeRy study group Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/09/2021.01.08.20248149.abstract N2 - Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking.Objective To determine the efficacy of lopinavir/ritonavir, lopinavir/ritonavir-IFN-β-1a, hydroxychloroquine or remdesivir for improving the clinical, virological outcomes in COVID-19 inpatients.Design Open-label, randomized, adaptive, controlled trial.Setting Multi-center trial with patients from France.Participants 583 COVID-19 inpatients requiring oxygen and/or ventilatory supportIntervention Standard of care (SoC, control), SoC plus lopinavir/ritonavir (400 mg lopinavir and 100 mg ritonavir every 12h for 14 days), SoC plus lopinavir/ritonavir plus IFN-ß-1a (44 μg of subcutaneous IFN-ß-1a on days 1, 3, and 6), SoC plus hydroxychloroquine (400 mg twice on day 1 then 400 mg once daily for 9 days) or SoC plus remdesivir (200 mg intravenously on day 1 then 100 mg once-daily for hospitalization duration or 10 days).Measurements The primary outcome was the clinical status at day 15, measured by the WHO 7-point ordinal scale. Secondary outcomes included SARS-CoV-2 quantification in respiratory specimens and safety analyses.Results Adjusted Odds Ratio (aOR) for the WHO 7-point ordinal scale were not in favor of investigational treatments: lopinavir/ritonavir versus control, aOR 0.83, 95%CI, 0.55 to 1.26, P=0.39; lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69, 95%CI, 0.45 to 1.04, P=0.08; hydroxychloroquine versus control, aOR 0.93, 95%CI, 0.62 to 1.41, P=0.75. No significant effect on SARS-CoV-2 RNA clearance in respiratory tract was evidenced. Lopinavir/ritonavir-containing treatments were significantly associated with more SAE.Limitations Not a placebo-controlled, no anti-inflammatory agents tested.Conclusion No improvement of the clinical status at day 15 nor SARS-CoV-2 RNA clearance in respiratory tract specimens by studied drugs. This comforts the recent Solidarity findings.Registration NCT04315948.Funding PHRC 2020, Dim OneHealth, REACTingCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04315948Funding StatementThe trial was funded by grants from Programme Hospitalier de Recherche Clinique (PHRC-20-0351) (Ministry of Health), from the DIM One Health Ile-de-France (R20117HD) and from REACTing, a French multi-disciplinary collaborative network working on emerging infectious diseases. The funding sources had no role in the analysis of the data nor in the decision of publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Ethics Committee (CPP Ile-de-France-III, approval #20.03.06.51744).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonnable request to the corresponding author ER -